21 completed, 9 terminated, 3 unknown, 2 withdrawn. 36 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 21, Terminated 9, Unknown 3, Withdrawn 2, Active not recruiting 1 |
| Phase 2 | 12 | Completed 7, Terminated 4, Unknown 1 |
Follow Stage IV Melanoma: new trials by email Literature Review of Stage IV Melanoma trials Research Report on Stage IV Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients Cyclophosphamide, Fludarabine, Lifileucel - Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Richard Wu | 2 | 2022-07-01 | 2026-02-24 |
| Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors ImmunicomAIAC - Stage IV Non-small Cell Lung Cancer, Stage IV Melanoma | Phase 1 | Unknown | Dr. Ronnie Shapira | 30 | 2020-02-24 | 2021-03-24 |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors TBX-3400 - Stage III Melanoma, Stage IV Melanoma | Phase 1 | Unknown | Taiga Biotechnologies, Inc. | 72 | 2019-06-02 | 2022-05-03 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Pembrolizumab with All-Trans Retinoic Acid - Stage IV Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 26 | 2017-10-31 | 2024-10-01 |
| Radiation Use During Vemurafenib Treatment Radiation therapy, Vemurafenib - BRAFV600 Mutation, Stage IV Melanoma | Phase 1 | Withdrawn | University of Utah | 2017-06-01 | 2017-05-24 | |
| A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation - Stage IV Melanoma | Phase 1 / Phase 2 | Unknown | Virogen Biotechnology Inc. | 63 | 2017-01-01 | 2016-12-13 |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma IMP321 (eftilagimod alpha), Pembrolizumab - Stage IV Melanoma, Stage III Melanoma | Phase 1 | Completed | Immutep Australia Pty. Ltd. | 24 | 2016-04-01 | 2019-12-18 |
| Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma lymph node, X-ACT - Stage IIIC Skin Melanoma, Stage IV Melanoma | Phase 1 | Terminated | Case Comprehensive Cancer Center | 3 | 2015-03-17 | 2018-12-06 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Indoximod, Ipilimumab, Nivolumab - Metastatic Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 131 | 2014-07-01 | 2026-05-29 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS) - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 17 | 2012-11-09 | 2025-05-16 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2012-03-01 | 2014-04-21 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide - Stage IV Melanoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 12 | 2010-04-01 | 2011-12-21 |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma Lenvatinib, Dacarbazine - Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Eisai Inc. | 97 | 2010-04-01 | 2016-10-10 |
| Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 25 | 2010-02-01 | 2020-04-07 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer cediranib maleate, whole-brain radiation therapy - Male Breast Cancer, Stage IV Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2009-08-01 | 2013-03-08 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, cyclophosphamide, biopsy - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2009-02-01 | 2017-04-19 |
Showing 20 of 36. Sign in to see all of them.
Melanoma (36) · Carcinoma, Renal Cell (7) · Brain Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (3) · Breast Neoplasms, Male (3) · Carcinoma, Ovarian Epithelial (2) · Colonic Neoplasms (2) · Astrocytoma (1) · Carcinoma, Islet Cell (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1) · Congenital Abnormalities (1) · Ependymoma (1) · Esthesioneuroblastoma, Olfactory (1)
Neoplasms by Histologic Type (36) · Neoplasms by Site (36) · Neoplasms, Germ Cell and Embryonal (36) · Neoplasms, Nerve Tissue (36) · Neuroectodermal Tumors (36) · Neuroendocrine Tumors (36) · Nevi and Melanomas (36) · Skin Diseases (36) · Skin and Connective Tissue Diseases (36) · Neoplasms (35) · Skin Neoplasms (35) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms, Glandular and Epithelial (9) · Urogenital Diseases (9)
Cyclophosphamide (7) · Interleukin-2 (6) · aldesleukin (6) · Biopsy (5) · Immunohistochemistry (5) · Polymerase Chain Reaction (5) · pembrolizumab (5) · Ipilimumab (4) · Vemurafenib (3) · CTLA-4 Antigen (2) · Dacarbazine (2) · Immunologic Techniques (2) · Introns (2) · Nivolumab (2) · Radiosurgery (2)
National Cancer Institute (NCI) (10) · Fred Hutchinson Cancer Center (5) · Case Comprehensive Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Abramson Cancer Center at Penn Medicine (1) · Dr. Ronnie Shapira (1) · Eisai Inc. (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Immutep Australia Pty. Ltd. (1) · John P. Fruehauf (1) · Kyowa Kirin, Inc. (1) · Mayo Clinic (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · NewLink Genetics Corporation (1) · Richard Wu (1)
United States (32) · Australia (2) · Germany (1) · Israel (1) · Italy (1) · Spain (1) · United Kingdom (1)
Cassian Yee (3) · Frank Hodi (2) · Sylvia Lee (2) · Wenyin Shi, MD, PhD (2) · Andres Forero, MD (1) · April Eichler (1) · Aude Chapuis (1) · Dave Harish (1) · David Solit (1) · Ernest C. Borden, MD (1) · Gary Hudes (1) · Jason Chesney, MD, PhD (1) · Jason Luke (1) · Jeffrey Weber (1) · John Fruehauf, MD (1)
PMID 25795722, PMID 27269940, PMID 28816150
K12CA076930 (3), U01CA062490 (3), P30CA006516 (2), N01CM62202 (1), P30CA012197 (1), P30CA016672 (1), P30CA043703 (1), R21CA105776 (1), R21CA128283 (1), R21CA137647 (1), U01CA062505 (1), U01CA069856 (1), UM1CA186709 (1)